| Literature DB >> 31032355 |
Ping Nie1, Rui Chen2, Manyu Luo1, Changqing Dong1, Liangmei Chen1, Juan Liu1, Liangqian Hu1, Bing Li1, Ping Luo1.
Abstract
PURPOSE: To identify the epidemiology and pathological types of kidney diseases and their changes during the past decade, in a population from Northeast China.Entities:
Mesh:
Year: 2019 PMID: 31032355 PMCID: PMC6457280 DOI: 10.1155/2019/6869179
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Pathological types of kidney diseases during different periods.
| Pathological types | 2008-12 | 2013-17 | 2008-17 | |||
|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | |
| PGN | 1748 | (72.1) | 1845 | (74.2) | 3593 | (73.2) |
| SGN | 594 | (24.5) | 571 | (23.0) | 1165 | (23.7) |
| TIN | 73 | (3.0) | 66 | (2.6) | 139 | (2.8) |
| HN | 9 | (0.4) | 4 | (0.2) | 13 | (0.3) |
| Total | 2424 | (100) | 2486 | (100) | 4910 | (100) |
Abbreviations. PGN: primary glomerulonephritis; SGN: secondary glomerulonephritis; TIN: tubular-interstitial nephropathy; HN: hereditary nephropathy.
Figure 1Percentages of patients diagnosed with kidney diseases who were in different age groups during different periods (n = 4910).
Figure 2Percentage of patients diagnosed with kidney disease who were elderly (≥60 years-old), from 2008 to 2017.
Figure 3Pathological types of PGN during different periods. p < 0.05, p < 0.01, and p < 0.001 by the chi-square test. Abbreviations: IgAN: IgA nephropathy; MN: membranous nephropathy; MsPGN: mesangial proliferative glomerulonephritis; MCD: minimal change disease; GML: glomerular minor lesion; FSGS: focal segmental glomerulosclerosis; MPGN: membranoproliferative glomerulonephritis; EnPGN: endocapillary proliferative glomerulonephritis; CreGN: crescentic glomerulonephritis; others: proliferative sclerosis and sclerosing glomerulonephritis.
Figure 4Changes in the percentages of PGN cases with MN and IgAN, from 2008 to 2017.
Pathological types of SGN during different periods.
| Pathological types | 2008-12 | 2013-17 | 2008-17 |
| |||
|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | ||
|
| 348 | (58.6) | 266 | (46.6) | 614 | (52.7) | <0.001 |
| LN | 209 | (35.2) | 187 | (32.7) | 396 | (34.0) | 0.380 |
| HSPN | 135 | (22.7) | 74 | (13.0) | 209 | (17.9) | <0.001 |
| SSARD | 4 | (0.7) | 3 | (0.5) | 7 | (0.6) | 1.000 |
| MCTARD | 0 | (0) | 2 | (0.4) | 2 | (0.2) | 0.240 |
|
| 86 | (14.5) | 145 | (25.4) | 231 | (19.8) | <0.001 |
| HTARD | 38 | (6.4) | 63 | (11.0) | 101 | (8.7) | 0.005 |
| MHTARD | 26 | (4.4) | 26 | (4.5) | 52 | (4.4) | 0.884 |
| SVARD | 14 | (2.3) | 54 | (9.5) | 68 | (5.8) | <0.001 |
| IN | 7 | (1.2) | 2 | (0.4) | 9 | (0.8) | 0.201 |
| HUS | 1 | (0.2) | 0 | (0) | 1 | (0.1) | 1.000 |
|
| 94 | (15.8) | 128 | (22.4) | 222 | (19.1) | 0.004 |
| DN | 53 | (8.9) | 83 | (14.5) | 136 | (11.7) | 0.003 |
| AN | 26 | (4.4) | 27 | (4.7) | 53 | (4.5) | 0.774 |
| LCDD | 2 | (0.3) | 8 | (1.4) | 10 | (0.9) | 0.099 |
| C3GN | 0 | (0) | 2 | (0.4) | 2 | (0.2) | 0.240 |
| LPN | 0 | (0) | 1 | (0.2) | 1 | (0.1) | 0.490 |
| CUAN | 1 | (0.2) | 0 | (0) | 1 | (0.1) | 1.000 |
| OAG | 8 | (1.3) | 4 | (0.7) | 12 | (1.0) | 0.423 |
| ING | 4 | (0.7) | 3 | (0.5) | 7 | (0.6) | 1.000 |
|
| 66 | (11.1) | 32 | (5.6) | 98 | (8.4) | 0.001 |
| HBV-GN | 65 | (10.9) | 31 | (5.4) | 96 | (8.2) | 0.001 |
| HCV-GN | 1 | (0.2) | 1 | (0.2) | 2 | (0.2) | 1.000 |
|
| 594 | (100) | 571 | (100) | 1165 | (100) | - |
Abbreviations: LN, lupus nephritis; HSPN, Henoch-Schönlein purpura nephritis; SSARD, Sjogren's syndrome associated renal damage; MCTARD, Mixed connective tissue disease associated renal damage; HT/MHTARD, hypertension/malignant hypertension-associated renal damage; SVARD, systemic vasculitis-associated renal damage; IN, ischemic nephropathy; HUS, hemolysis aemolytic uraemic syndrome; DN, diabetic nephropathy; AN, amyloidosis nephropathy; LCDD, light chain deposition nephropathy; C3GN, C3 glomerulopathy; LPN, lipoprotein glomerulopathy; CUAN, chronic uric acid nephropathy; OAG, obesity-associated glomerulopathy; ING, idiopathic nodular glomerulosclerosis; HBV-GN, hepatitis B virus associated nephritis; HCV-GN, hepatitis C virus associated nephritis.
Figure 5Pathological types of SGN during different periods. p < 0.05, p < 0.01, and p < 0.001 by the chi-square test. Abbreviations. LN: lupus nephritis; HSPN: Henoch-Schönlein purpura nephritis; DN: diabetic nephropathy; HT/MHTARD: hypertension/malignant hypertension-associated renal damage; HBV-GN: hepatitis B virus associated nephritis; SVARD: systemic vasculitis-associated renal damage; AN: amyloidosis nephropathy; OAG: obesity-associated glomerulopathy; LCDD: light chain deposition nephropathy; IN: ischemic nephropathy; others: SSARD: Sjogren's syndrome associated renal damage; MCTARD: mixed connective tissue disease associated renal damage; HUS: hemolysis aemolytic uraemic syndrome; C3GN: C3 glomerulopathy; LPN: lipoprotein glomerulopathy; CUAN: chronic uric acid nephropathy; ING: idiopathic nodular glomerulosclerosis.
Pathological types of kidney diseases in different age groups during different periods.
| Age group | Pathological types | 2008-12 | 2013-17 | 2008-17 |
| |||
|---|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | |||
|
| MN | 54 | (11.2) | 38 | (13.4) | 92 | (12.0) | 0.356 |
| IgAN | 117 | (24.2) | 71 | (25.1) | 188 | (24.5) | 0.788 | |
| MCD | 58 | (12.0) | 65 | (23.0) | 123 | (16.1) | <0.001 | |
| MsPGN | 70 | (14.5) | 10 | (3.5) | 80 | (10.4) | <0.001 | |
| LN | 50 | (10.4) | 35 | (12.4) | 85 | (11.1) | 0.391 | |
| HSPN | 51 | (10.6) | 20 | (7.1) | 71 | (9.3) | 0.108 | |
| HT/MHTARD | 4 | (0.8) | 5 | (1.8) | 9 | (1.2) | 0.414 | |
| DN | 1 | (0.2) | 0 | (0) | 1 | (0.1) | 1.000 | |
| Others | 78 | (16.1) | 39 | (13.8) | 117 | (15.3) | 0.379 | |
|
| MN | 110 | (11.0) | 211 | (25.1) | 321 | (17.4) | <0.001 |
| IgAN | 375 | (37.4) | 241 | (28.6) | 616 | (33.4) | <0.001 | |
| MCD | 61 | (6.1) | 77 | (9.1) | 138 | (7.5) | 0.013 | |
| MsPGN | 106 | (10.6) | 22 | (2.6) | 128 | (6.9) | <0.001 | |
| LN | 103 | (10.3) | 97 | (11.5) | 200 | (10.8) | 0.393 | |
| HSPN | 46 | (4.6) | 17 | (2.0) | 63 | (3.4) | 0.002 | |
| HT/MHTARD | 34 | (3.4) | 39 | (4.6) | 73 | (4.0) | 0.174 | |
| DN | 9 | (0.9) | 23 | (2.7) | 32 | (1.7) | 0.003 | |
| Others | 158 | (15.8) | 115 | (13.7) | 273 | (14.8) | 0.204 | |
|
| MN | 157 | (23.5) | 425 | (50.0) | 582 | (38.4) | <0.001 |
| IgAN | 138 | (20.7) | 82 | (9.6) | 220 | (14.5) | <0.001 | |
| MCD | 41 | (6.1) | 61 | (7.2) | 102 | (6.7) | 0.427 | |
| MsPGN | 57 | (8.5) | 14 | (1.6) | 71 | (4.7) | <0.001 | |
| LN | 52 | (7.8) | 37 | (4.4) | 89 | (5.9) | 0.005 | |
| HSPN | 27 | (4.0) | 18 | (2.1) | 45 | (3.0) | 0.028 | |
| HT/MHTARD | 19 | (2.8) | 29 | (3.4) | 48 | (3.2) | 0.534 | |
| DN | 30 | (4.5) | 38 | (4.5) | 68 | (4.5) | 0.980 | |
| Others | 146 | (21.9) | 146 | (17.2) | 292 | (19.2) | 0.021 | |
|
| MN | 94 | (34.6) | 248 | (48.5) | 342 | (43.7) | <0.001 |
| IgAN | 23 | (8.5) | 26 | (5.1) | 49 | (6.3) | 0.064 | |
| MCD | 21 | (7.7) | 50 | (9.8) | 71 | (9.1) | 0.338 | |
| MsPGN | 25 | (9.2) | 8 | (1.6) | 33 | (4.2) | <0.001 | |
| LN | 4 | (1.5) | 18 | (3.5) | 22 | (2.8) | 0.154 | |
| HSPN | 11 | (4.0) | 19 | (3.7) | 30 | (3.8) | 0.821 | |
| HT/MHTARD | 7 | (2.6) | 16 | (3.1) | 23 | (2.9) | 0.660 | |
| DN | 13 | (4.8) | 22 | (4.3) | 35 | (4.5) | 0.760 | |
| Others | 74 | (27.2) | 104 | (20.4) | 178 | (22.7) | 0.029 | |
|
| MN | 415 | (17.1) | 922 | (37.1) | 1337 | (27.2) | <0.001 |
| IgAN | 653 | (26.9) | 420 | (16.9) | 1073 | (21.9) | <0.001 | |
| MCD | 181 | (7.5) | 253 | (10.2) | 434 | (8.8) | 0.001 | |
| MsPGN | 258 | (10.6) | 54 | (2.2) | 312 | (6.4) | <0.001 | |
| LN | 209 | (8.6) | 187 | (7.5) | 396 | (8.1) | 0.157 | |
| HSPN | 135 | (5.6) | 136 | (5.5) | 271 | (5.5) | 0.880 | |
| HT/MHTARD | 64 | (2.6) | 89 | (3.6) | 153 | (3.1) | 0.058 | |
| DN | 53 | (2.2) | 83 | (3.3) | 136 | (2.8) | 0.014 | |
| Others | 456 | (18.8) | 342 | (13.8) | 798 | (16.3) | <0.001 | |
Clinical manifestations and pathological types of PGN.
| Pathological types | AGN | CGN | NS | RPGN | AUA | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | (%) | N | (%) | N | (%) | N | (%) | N | (%) | ||
| IgAN | 1 | (3.8) | 799 | (55.6) | 196 | (9.9) | 0 | (0) | 77 | (63.1) | 1073 |
| MsPGN | 0 | (0) | 90 | (6.3) | 214 | (10.8) | 0 | (0) | 8 | (6.6) | 312 |
| MN | 0 | (0) | 305 | (21.2) | 1026 | (51.8) | 0 | (0) | 6 | (4.9) | 1337 |
| FSGS | 0 | (0) | 46 | (3.2) | 64 | (3.2) | 0 | (0) | 0 | (0) | 110 |
| MCD | 0 | (0) | 0 | (0) | 422 | (21.3) | 0 | (0) | 0 | (0) | 123 |
| GML | 0 | (0) | 91 | (6.3) | 1 | (0.1) | 0 | (0) | 31 | (25.4) | 422 |
| CreGN | 0 | (0) | 1 | (0.1) | 0 | (0) | 29 | (100) | 0 | (0) | 30 |
| MPGN | 2 | (7.7) | 16 | (1.1) | 37 | (1.9) | 0 | (0) | 0 | (0) | 55 |
| EnPGN | 23 | (88.5) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 23 |
| Others | 0 | (0) | 89 | (6.2) | 19 | (1.0) | 0 | (0) | 0 | (0) | 108 |
|
|
|
|
|
|
|
|
|
|
|
|
|